Loading clinical trials...

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial | Clinical Trials | Clareo Health

RECRUITINGNANCT05652673

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first...

Lead sponsor: Erasmus Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITING

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

NCT07528066 · Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, and more

RECRUITINGPhase 1/2

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926 · Melanoma Stage IV, Solid Tumor

RECRUITINGNA

Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy

NCT05689463 · Patients With Chronic Pruritus for More Than 1 Month Who Have Received Immunotherapy

RECRUITINGPhase 2

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

NCT03340129 · Melanoma Stage Iv

RECRUITINGPhase 2

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

NCT04562129 · Melanoma Stage III, Melanoma Stage IV, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 28, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment80

Start dateFeb 2023

Last updatedFeb 28, 2025

Condition

Melanoma Stage IV Melanoma Stage III Immunotherapy Toxicity, Drug

Locations shown

Erasmus MC

Rotterdam

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 28, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions